GC Biopharma 
Welcome,         Profile    Billing    Logout  
 38 Products   113 Diseases  38 Products   52 Trials   1462 News 
63 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Margenza (margetuximab-cmkb) / TerSera Therap
2019-004699-21: Study of Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in HER2-Positive Gastric or Gastroesophageal Junction Cancer

Not yet recruiting
2/3
860
Europe, RoW
Margetuximab, INCMGA00012, MGD013, Trastuzumab, MGAH22, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Herceptin
MacroGenics, Inc., MACROGENICS, INC., MacroGenics, Inc., Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator),  Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator), Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator)
Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer, Gastric Cancer or Gastroesophageal Junction Cancer, Diseases [C] - Cancer [C04]
 
 
MAHOGANY, NCT04082364 / 2019-004699-21: Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

Checkmark Interim data from cohort A part 1 of MAHOGANY trial in combination with retifanlimab for advanced HER2+ gastric cancer at ESMO 2021
Sep 2021 - Sep 2021: Interim data from cohort A part 1 of MAHOGANY trial in combination with retifanlimab for advanced HER2+ gastric cancer at ESMO 2021
Checkmark Safety and efficacy data from cohort A of MAHOGANY trial in combination with INCMGA00012 for gastroesophageal junction cancerat ESMO 2021
Sep 2021 - Sep 2021: Safety and efficacy data from cohort A of MAHOGANY trial in combination with INCMGA00012 for gastroesophageal junction cancerat ESMO 2021
Hourglass Sep 2020 - Mar 2021 : Completion of enrollment of module A of MAHOGANY trial
More
Completed
2/3
82
Europe, US, RoW
margetuximab, MGAH22, Margenza®, Retifanlimab, MGA012, INCMGA00012, Tebotelimab, MGD013, Trastuzumab, Herceptin, Chemotherapy
MacroGenics, Zai Lab (Shanghai) Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
01/24
03/25
NCT04262804: A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Active, not recruiting
2
123
RoW
Margetuximab, Trastuzumab, Chosen Chemotherapy (Capecitabine), Chosen Chemotherapy (Vinorelbine ), Chosen Chemotherapy (Gemcitabine )
Zai Lab (Shanghai) Co., Ltd.
Breast Cancer Metastatic
09/21
12/23
MARGOT, NCT04425018: MARGetuximab Or Trastuzumab

Active, not recruiting
2
174
US
Paclitaxel, Taxol, Onxal, Pertuzumab, Perjeta, Margetuximab, Margenza, Trastuzumab, Herceptin, Kanjinti, Ogivri, Herzuma
Dana-Farber Cancer Institute, MacroGenics, Translational Breast Cancer Research Consortium
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
10/24
07/27
NCT03219268: A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Checkmark Data from trial for DLBCL at ASH 2020
Dec 2020 - Dec 2020: Data from trial for DLBCL at ASH 2020
Checkmark Data from trial in combination with Margetuximab for patients with unresectable or metastatic neoplasms at SITC 2020
Nov 2020 - Nov 2020: Data from trial in combination with Margetuximab for patients with unresectable or metastatic neoplasms at SITC 2020
Checkmark Data from trial in combination with Margetuximab for patients with unresectable or metastatic neoplasms at ASCO 2020
More
Completed
1
277
Europe, US, RoW
tebotelimab 1 mg, MGD013, tebotelimab 3 mg, tebotelimab 10 mg, tebotelimab 30 mg, tebotelimab 120 mg, tebotelimab 300 mg, tebotelimab 400 mg, tebotelimab 600 mg, tebotelimab 800 mg, tebotelimab 1200 mg, margetuximab, MGAH22, Margenza
MacroGenics
Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Cervical Cancer, TNBC - Triple-Negative Breast Cancer
02/23
02/23
GreenGene F (beroctocog alfa) / BMS, GC Biopharma
2012-001445-40: To determine the safety, effectiveness, and effect on the body of GreenGene F in previously treated patients 12 years of age or older who have severe Hemophilia A.

 
3
25
Europe, RoW
GreenGene F, ReFacto AF, ReFacto AF
Green Cross Corporation, Green Cross Corporation
Haemophilia A
 
04/15
marzeptacog alfa (CB 813d) / GC Biopharma
2020-003371-18: Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Marzeptacog alfa (activated) in Treatment of Episodic Bleeding in Subjects with Factor VII deficiency, Glanzmann thrombasthenia, and Haemophilia A with inhibitors on prophylaxis Studio per valutare farmacocinetica, farmacodinamica, sicurezza ed efficacia di marzeptacog alfa (attivato) nel trattamento degli episodi emorragici in soggetti con il deficit di fattore VII, tromboastenia di Glanzmann o l’emofilia A con inibitori attualmente in trattamento preventivo con una dose di emicizumab.

Not yet recruiting
1/2
24
Europe
Marzeptacog alfa (activated), [MarzAA, CB813d, PF-05280602], Powder for solution for injection
Catalyst Biosciences, Inc., Catalyst Biosciences, Inc.
Factor VII deficiency, Glanzmann thrombasthenia (GT) and Hemophilia A with inhibitors on emicizumab prophylaxis (HAwI-E) deficit di fattore VII, tromboastenia di Glanzmann (GT) e l’emofilia A con inibitori attualmente in trattamento preventivo con una dose di emicizumab (HAwI-E)., Inherited rare bleeding disorders in which blood cannot clot normally difetti ereditari della coagulazioni in cui il sangue non è in grado di coagulare normalmente, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
Pexa-Vec (pexastimogene devacirepvec) / SillaJen
ACTRN12620001286932: Investigating the effect of a virus-based immunotherapy as a pre-surgical treatment for prostate cancer

Recruiting
2
30
 
Royal Melbourne Hospital, Movember, Medical Research Future Fund
Prostate Cancer
 
 
JX594-REN026, NCT03294083: A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

Active, not recruiting
1b/2a
89
US, RoW
Pexastimogene Devacirepvec (Pexa-Vec), JX-594, Cemiplimab
SillaJen, Inc., Regeneron Pharmaceuticals
Renal Cell Carcinoma
08/23
11/23
2016-000085-32: The purpose of this study is to evaluate the safety and efficacy of the combination of two products Pexa-Vec and nivolumab for the treatment of liver cancer L'obiettivo dello studio clinico è di valutare la sicurezza e l'efficacia della combinazione dei due prodotti Pexa-Vec e nivolumab per il trattamento del tumore del fegato

Not yet recruiting
1/2
55
Europe
pexastimogene devacirepvec, nivolumab, [Pexa-Vec], [nivolumab], Suspension for injection, Concentrate for solution for infusion, OPDIVO - 10 MG/ML- CONCENTRATO PER SOLUZIONE PER INFUSIONE- USO ENDOVENOSO- FLACONCINO (VETRO)- 4 ML- 1 FLACONCINO
TRANSGENE SA, TRANSGENE
Hepatocellular carcinoma Carcinoma epatocellulare, Liver cancer Tumore del fegato, Diseases [C] - Cancer [C04]
 
 
NCT03206073: A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Checkmark Results in combination with Pexa-Vec with failed MSS and MSI-H colorectal cancer
Jan 2019 - Jan 2019: Results in combination with Pexa-Vec with failed MSS and MSI-H colorectal cancer
Completed
1/2
34
US
Durvalumab, MEDI-4736, Tremelimumab, CP-675,206, Pexa-Vec, Pexa-Vec, INN pexastimogene devacirepvec
National Cancer Institute (NCI)
Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma, Refractory Cancer, Colorectal Neoplasms
09/20
06/22
NCT04849260: Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma

Recruiting
1/2
54
RoW
Pexa-Vec combined with ZKAB001, ZKAB001 monotherapy
Lee's Pharmaceutical Limited
Local Progression or Metastatic Melanoma With Failed First-line Treatment
05/22
05/23
METROmaJX, NCT02630368: A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma

Checkmark Results for HER2-ve breast cancer and soft tissue sarcoma in combination with metronomic cyclophosphamide
Sep 2018 - Sep 2018: Results for HER2-ve breast cancer and soft tissue sarcoma in combination with metronomic cyclophosphamide
Recruiting
1/2
197
Europe
Cyclophosphamide and JX-594 dose escalation, Brand name : ENDOXAN, Brand name: Pexa-Vec, Cyclophosphamide and JX-594, Cyclophosphamide, Avelumab and JX-594 and Cyclophosphamide, Brand name: ENDOXAN, Brand name: Avelumab
Institut Bergonié, National Cancer Institute, France, Fondation ARC, Merck Sharp & Dohme LLC, Transgene
Solid Tumors, Soft-tissue Sarcoma, Breast Cancer
05/23
11/24
Immuncell-LC (GCC4002) / GC Biopharma
NCT04969731: Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

Recruiting
3
408
RoW
Immuncell-LC, Autologous activated T lymphocyte, Gemcitabine
GC Cell Corporation
Pancreatic Ductal Adenocarcinoma
12/26
06/27
NCT02856815: Safety and Efficacy of "Immuncell-LC" in TACE Therapy

Completed
2
76
RoW
Immuncell-LC
GC Cell Corporation
Carcinoma, Hepatocellular
08/20
09/22
NCT03983967: Evaluate the Efficacy and Safety of 'Immuncell-LC' in Patients Undergoing Liver Transplantation

Completed
1/2
19
RoW
Immuncell-LC
GC Cell Corporation
Liver Transplantation
09/21
08/22
NCT05053295: Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo) in Subjects With Advanced or Recurrent Gastric Cancer

Recruiting
N/A
20
RoW
autologous activated T lymphocyte, Immuncell-LC (Autologous activated T lymphocyte),
Gangnam Severance Hospital
Relapsed or Advanced Gastric Adenocarcinoma, Gastro-esophageal Junction Cancer
07/23
09/23
NCT06620510: Retrospective Study of Long-Term Survival of "Immuncell-LC" in Patients Undergoing Curative Resection for HCC in Korea

Not yet recruiting
N/A
230
NA
Immuncell-LC, No Interventions
GC Cell Corporation
Hepatocellular Carcinoma
12/24
07/25
HyPoietin (epoetin alfa biosimilar) / GC Biopharma, Genexine, Fosun Pharma
NCT04155125: A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient

Completed
3
391
RoW
efepoetin alfa, Mircera
PT Kalbe Genexine Biologics, Novotech (Australia) Pty Limited
Anaemia Associated With Chronic Kidney Disease
03/22
06/23
NCT06466785: A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

Recruiting
3
429
RoW
Efepoetin Alfa, GX-E4, Darbepoetin Alfa, Aranesp®
Genexine, Inc., PT Kalbe Genexine Biologics
Anemia of Chronic Kidney Disease
12/26
09/27
GX-E4-HV-003, NCT06490939: Clinical Trial of Efepoetin Alfa in Healthy Subjects

Recruiting
1
40
RoW
Efepoetin Alfa, GX-E4
Genexine, Inc.
Healthy
02/25
10/25
Neulapeg (pegfilgrastim biosimilar) / GC Biopharma
NCT02840539: Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma

Completed
2
19
RoW
Bortezomib, Cytarabine, Dexamethasone, Pegteograstim, Protezomib, Cytarabine, Dexamethasone, Neulapeg
Seoul National University Hospital, Consortium for Improving Survival of Lymphoma
Mantle Cell Lymphoma
03/21
12/22
NCT06353581: Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX

Active, not recruiting
2
78
RoW
Neulapeg, Control
Yonsei University
Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
05/24
05/24
Barycela (varicella II vaccine) / GC Biopharma
NCT05422508: Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

Recruiting
2
230
RoW
MG1111 (BARICELA), VARIVAX, Suduvax
Green Cross Corporation
Varicella
06/25
06/27
NCT05664152: An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years

Not yet recruiting
N/A
250
NA
MG1111
GC Biopharma Corp
Varicella Zoster Virus Infection
04/23
06/23
Hunterase (recombinant human iduronate-2-sulfatase) / GC Biopharma
NCT05422482: A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ

Active, not recruiting
1
12
RoW
GC1123
GC Biopharma Corp
Mucopolysaccharidosis II, Hunter Syndrome
06/27
06/27
GC3111A / GC Biopharma
NCT06997627: A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults

Recruiting
1/2
120
RoW
GC3111B, Boostrix®
GC Biopharma Corp
Tetanus-diphtheria-acellular Pertussis (Tdap)
05/26
05/26
Hepabig-gene (lenvervimab) / GC Biopharma
NCT05686759: A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.

Recruiting
3
105
RoW
Undiluted I.V.-Hepabig inj(GC5103), Diluted I.V.-Hepabig inj(GC5103)
GC Biopharma Corp
Hepatitis B
06/26
06/26
NCT03519113: HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102

Active, not recruiting
2/3
186
RoW
GC1102 80,000 IU, GC1102 100,000 IU, I.V HBIG
Green Cross Corporation
Hepatitis B Infection
03/22
09/22
GC-1118A / GC Biopharma
NCT04077255: EGFR-targeted Therapy for Gastric Cancer

Recruiting
2
19
RoW
Anti-EGFR antibody in combination with weekly paclitaxel, GC-1118 in combination with weekly paclitaxel
National Cancer Center, Korea, Korean Cancer Study Group
Adenocarcinoma of the Stomach
12/23
12/23
MG1113A / GC Biopharma
NCT05493631: A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient

Recruiting
1b
15
RoW
MG1113
GC Biopharma Corp
Hemophilia
07/24
12/24
Enblo (enavogliflozin) / Daewoong Pharma, GC Biopharma, M8 Pharma
ENVELOP, NCT06642623: A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients

Recruiting
4
2862
RoW
Enavogliflozin, Dapagliflozin or Empagliflozin
Yonsei University
Diabetes Mellitus, Type 2, Cardiovascular Diseases, Kidney Diseases
09/29
12/30
NCT06399835: Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

Recruiting
4
120
RoW
Enavogliflozin, Envlo Tab., Pioglitazone, Actos Tab.
Seoul National University Bundang Hospital, Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes
06/26
12/26
ENRICH-PEF, NCT06350487: The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction

Not yet recruiting
4
154
RoW
SGLT2 inhibitor, SGLT2 inhibitor: Enavogliflozin (Brand names: Envlo tab)
Samsung Medical Center
Heart Failure, Preserved Ejection Fraction
12/25
06/26
ENAVO-AF, NCT06528262: Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation

Not yet recruiting
4
390
RoW
Enavogliflozin, Placebo
Yonsei University
Atrial Fibrillation
08/26
08/26
ENDEAVOR-HCM, NCT06580717: ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy

Recruiting
4
200
RoW
enavogliflozin 0.3mg, enavogliflozin Placebo
Yonsei University
Nonobstructive Hypertrophic Cardiomyopathy
11/26
11/26
ENVY, NCT06782139: Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity

Recruiting
4
30
RoW
Enavogliflozin, Placebo
Korea University Anam Hospital, Daewoong Pharmaceutical Co. LTD.
Obesity and Type 2 Diabetes
12/25
12/25
ENAVO-TAVR, NCT05672836: ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement

Recruiting
4
1040
RoW
Enavogliflozin, Standard-of-Care, Standard-of-Care medical therapy
Duk-Woo Park, MD, CardioVascular Research Foundation, Korea, Daewoong Pharmaceutical Co. LTD.
Aortic Valve Stenosis, Heart Failure
12/26
04/27
NCT06141980: Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus

Not yet recruiting
3
134
NA
DWP16001 0.3 mg
Daewoong Pharmaceutical Co. LTD.
T2DM (Type 2 Diabetes Mellitus)
09/25
09/25
NCT05505994: The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin

Active, not recruiting
3
340
RoW
DWP16001, DWP16001 tablet, Dapagliflozin, Dapagliflozin tablet, DWP16001 Placebo, DWP16001 Placebo tablet, Dapagliflozin Placebo, Dapagliflozin Placebo tablet
Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
02/24
09/24
ENHANCE-I, NCT05466643: A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus

Recruiting
3
240
RoW
DWP16001 0.3mg, DWP16001 Placebo
Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes Mellitus
09/24
09/24
NCT06606093: Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients

Not yet recruiting
3
348
RoW
DWP16001 Placebo, DWP16001 0.3mg
Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetic Nephropathy
09/26
01/27
EVENT, NCT06027307: Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation

Recruiting
3
540
RoW
Enavogliflozin, Envlo (brand name), Placebo
Asan Medical Center, Daewoong Pharmaceutical Co. LTD.
Tricuspid Regurgitation, Heart Failure With Preserved Ejection Fraction
12/26
10/27
NCT05207176: Study to Evaluate the Safety and PK Properties of DWP16001 in Healthy Subjects With Various Ethnicities

Not yet recruiting
1
24
NA
DWP16001
Daewoong Pharmaceutical Co. LTD.
Healthy
04/22
08/22
NCT05321732: The Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy Adults

Enrolling by invitation
1
24
RoW
DWP16001, DWP202010
Daewoong Pharmaceutical Co. LTD.
Healthy Volunteers
08/22
08/22
NCT05500898: Drug-Drug Interaction of DWP16001 in Combination With DWC202204 and DWC202205 in Healthy Male Adults

Not yet recruiting
1
53
NA
DWP16001, DWC202204+DWC202205, DWP16001+DWC202204+DWC202205
Daewoong Pharmaceutical Co. LTD.
Healthy
10/22
02/23
NCT05737771: To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination

Recruiting
1
40
RoW
DWC202213, DWJ1563, DWP16001
Daewoong Pharmaceutical Co. LTD.
FDC, Diabetes Mellitus, Type 2
03/23
06/23
NCT05797922: To Evaluate the Effect of Food on the Safety and PK Characteristics of DWP16001 in Healthy Adult Volunteers

Recruiting
1
32
RoW
DWP16001, DWP16001 0.3mg
Daewoong Pharmaceutical Co. LTD.
Healthy
05/23
11/23
NCT05747664: To Compare the Safety and PK/PD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic Function

Recruiting
1
24
RoW
DWP16001, DWP16001 0.3mg
Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus, Type 2
04/24
04/24
DW_DWP16001112, NCT06644404: Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults

Not yet recruiting
1
34
RoW
DWP16001 0.3mg, DWC202407 1,000mg, DWC202408 2mg
Daewoong Pharmaceutical Co. LTD.
Healthy
12/24
04/25
NCT06427083: Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus

Recruiting
N/A
240
RoW
Envlo Tablet, Envolomet SR Tablet
Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes Mellitus
12/25
06/26
NCT05926414: To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus

Active, not recruiting
N/A
15000
RoW
Enavogliflozin, Envlo Tablet, Envlomet SR Tablet
Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus, Type 2
01/25
06/25
NCT06647888: Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia

Recruiting
N/A
12000
RoW
Envlo Tablet, Enavogliflozin 0.3mg, Envlomet SR Tablet, Enavogliflozin 0.3mg/ Metformin1,000mg
Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus, Type 2
12/25
06/26
AlloNK (GCC4001) / Artiva Biotherapeutics
NCT06991114: AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Recruiting
2
90
US
Allogeneic NK Cells
Artiva Biotherapeutics, Inc.
Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease
01/28
01/29
LuminICE-203, NCT05883449: Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL

Recruiting
2
154
US
AFM13, AB-101, Cyclophosphamide, Fludarabine, Interleukin-2
Affimed GmbH, Artiva Biotherapeutics, Inc.
Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma
04/26
11/27
NCT04673617: AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Active, not recruiting
1/2
45
US
AB-101, Rituximab, Interleukin-2, Cyclophosphamide, Fludarabine, Bendamustine
Artiva Biotherapeutics, Inc.
Non Hodgkin Lymphoma
08/24
12/25
AB-101-03, NCT06265220: AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Recruiting
1
51
US
AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab
Artiva Biotherapeutics, Inc.
Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLE
08/27
08/27
IRIS-RD-01, NCT06581562: Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

Recruiting
1
30
US
AB-101, ALLONK, RITUXIMAB, CYCLOPHOSPHAMIDE, FLUDARABINE, Rituximab, Cyclophosphamide, Fludarabine
IRIS Research and Development, LLC, Artiva Biotherapeutics, Inc.
Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
07/27
12/28
GCC2003 / Artiva Biotherapeutics
NCT05678205: A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

Not yet recruiting
1/2
133
US, RoW
AB-201, Cyclophosphamide, Fludarabine
Artiva Biotherapeutics, Inc.
Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
04/27
04/27
Laennec (human placenta hydrolyzate) / GC Biopharma
NCT06493799: In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop

Not yet recruiting
3
226
NA
LAENNEC (Human Placenta Hydrolysate) IV, LAENNEC (Human Placenta Hydrolysate) SC
Green Cross Wellbeing
Chronic Liver Disease
12/25
12/25
human tonsil-derived mesenchymal stem cell (CT303) / GC Biopharma
NCT05238532: Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With ARDS

Withdrawn
1
8
RoW
CT303
GC Cell Corporation
Acute Respiratory Distress Syndrome
02/23
02/23
NCT05258331: Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis

Recruiting
1
24
RoW
CT303
GC Cell Corporation
Moderate to Severe Plaque Psoriasis
08/24
12/24
quadrivalent cell-culture based influenza vaccine (GC3106) / GC Biopharma
NCT06020118: Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations

Completed
4
455
US
Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster), Sequential Vaccination (Influenza vaccine then mRNA COVID booster), Sequential Vaccination (mRNA COVID booster then Influenza vaccine)
Duke University, Centers for Disease Control and Prevention, Arizona State University, University Hospitals Cleveland Medical Center, University of Pittsburgh, Washington University School of Medicine, Valleywise Health, Cleveland VA Medical Center, Senders Pediatrics
Influenza, COVID-19
03/24
05/24
Suduvax / GC Biopharma
No trials found
GCFLU Quadrivalent (quadrivalent flu vaccine) / GC Biopharma
No trials found
AFM13/AB-101 / Affimed, GC Biopharma
No trials found
GCC2005 / Artiva Biotherapeutics
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Margenza (margetuximab-cmkb) / TerSera Therap
2019-004699-21: Study of Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in HER2-Positive Gastric or Gastroesophageal Junction Cancer

Not yet recruiting
2/3
860
Europe, RoW
Margetuximab, INCMGA00012, MGD013, Trastuzumab, MGAH22, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Herceptin
MacroGenics, Inc., MACROGENICS, INC., MacroGenics, Inc., Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator),  Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator), Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator)
Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer, Gastric Cancer or Gastroesophageal Junction Cancer, Diseases [C] - Cancer [C04]
 
 
MAHOGANY, NCT04082364 / 2019-004699-21: Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

Checkmark Interim data from cohort A part 1 of MAHOGANY trial in combination with retifanlimab for advanced HER2+ gastric cancer at ESMO 2021
Sep 2021 - Sep 2021: Interim data from cohort A part 1 of MAHOGANY trial in combination with retifanlimab for advanced HER2+ gastric cancer at ESMO 2021
Checkmark Safety and efficacy data from cohort A of MAHOGANY trial in combination with INCMGA00012 for gastroesophageal junction cancerat ESMO 2021
Sep 2021 - Sep 2021: Safety and efficacy data from cohort A of MAHOGANY trial in combination with INCMGA00012 for gastroesophageal junction cancerat ESMO 2021
Hourglass Sep 2020 - Mar 2021 : Completion of enrollment of module A of MAHOGANY trial
More
Completed
2/3
82
Europe, US, RoW
margetuximab, MGAH22, Margenza®, Retifanlimab, MGA012, INCMGA00012, Tebotelimab, MGD013, Trastuzumab, Herceptin, Chemotherapy
MacroGenics, Zai Lab (Shanghai) Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
01/24
03/25
NCT04262804: A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Active, not recruiting
2
123
RoW
Margetuximab, Trastuzumab, Chosen Chemotherapy (Capecitabine), Chosen Chemotherapy (Vinorelbine ), Chosen Chemotherapy (Gemcitabine )
Zai Lab (Shanghai) Co., Ltd.
Breast Cancer Metastatic
09/21
12/23
MARGOT, NCT04425018: MARGetuximab Or Trastuzumab

Active, not recruiting
2
174
US
Paclitaxel, Taxol, Onxal, Pertuzumab, Perjeta, Margetuximab, Margenza, Trastuzumab, Herceptin, Kanjinti, Ogivri, Herzuma
Dana-Farber Cancer Institute, MacroGenics, Translational Breast Cancer Research Consortium
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
10/24
07/27
NCT03219268: A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Checkmark Data from trial for DLBCL at ASH 2020
Dec 2020 - Dec 2020: Data from trial for DLBCL at ASH 2020
Checkmark Data from trial in combination with Margetuximab for patients with unresectable or metastatic neoplasms at SITC 2020
Nov 2020 - Nov 2020: Data from trial in combination with Margetuximab for patients with unresectable or metastatic neoplasms at SITC 2020
Checkmark Data from trial in combination with Margetuximab for patients with unresectable or metastatic neoplasms at ASCO 2020
More
Completed
1
277
Europe, US, RoW
tebotelimab 1 mg, MGD013, tebotelimab 3 mg, tebotelimab 10 mg, tebotelimab 30 mg, tebotelimab 120 mg, tebotelimab 300 mg, tebotelimab 400 mg, tebotelimab 600 mg, tebotelimab 800 mg, tebotelimab 1200 mg, margetuximab, MGAH22, Margenza
MacroGenics
Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Cervical Cancer, TNBC - Triple-Negative Breast Cancer
02/23
02/23
GreenGene F (beroctocog alfa) / BMS, GC Biopharma
2012-001445-40: To determine the safety, effectiveness, and effect on the body of GreenGene F in previously treated patients 12 years of age or older who have severe Hemophilia A.

 
3
25
Europe, RoW
GreenGene F, ReFacto AF, ReFacto AF
Green Cross Corporation, Green Cross Corporation
Haemophilia A
 
04/15
marzeptacog alfa (CB 813d) / GC Biopharma
2020-003371-18: Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Marzeptacog alfa (activated) in Treatment of Episodic Bleeding in Subjects with Factor VII deficiency, Glanzmann thrombasthenia, and Haemophilia A with inhibitors on prophylaxis Studio per valutare farmacocinetica, farmacodinamica, sicurezza ed efficacia di marzeptacog alfa (attivato) nel trattamento degli episodi emorragici in soggetti con il deficit di fattore VII, tromboastenia di Glanzmann o l’emofilia A con inibitori attualmente in trattamento preventivo con una dose di emicizumab.

Not yet recruiting
1/2
24
Europe
Marzeptacog alfa (activated), [MarzAA, CB813d, PF-05280602], Powder for solution for injection
Catalyst Biosciences, Inc., Catalyst Biosciences, Inc.
Factor VII deficiency, Glanzmann thrombasthenia (GT) and Hemophilia A with inhibitors on emicizumab prophylaxis (HAwI-E) deficit di fattore VII, tromboastenia di Glanzmann (GT) e l’emofilia A con inibitori attualmente in trattamento preventivo con una dose di emicizumab (HAwI-E)., Inherited rare bleeding disorders in which blood cannot clot normally difetti ereditari della coagulazioni in cui il sangue non è in grado di coagulare normalmente, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
Pexa-Vec (pexastimogene devacirepvec) / SillaJen
ACTRN12620001286932: Investigating the effect of a virus-based immunotherapy as a pre-surgical treatment for prostate cancer

Recruiting
2
30
 
Royal Melbourne Hospital, Movember, Medical Research Future Fund
Prostate Cancer
 
 
JX594-REN026, NCT03294083: A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

Active, not recruiting
1b/2a
89
US, RoW
Pexastimogene Devacirepvec (Pexa-Vec), JX-594, Cemiplimab
SillaJen, Inc., Regeneron Pharmaceuticals
Renal Cell Carcinoma
08/23
11/23
2016-000085-32: The purpose of this study is to evaluate the safety and efficacy of the combination of two products Pexa-Vec and nivolumab for the treatment of liver cancer L'obiettivo dello studio clinico è di valutare la sicurezza e l'efficacia della combinazione dei due prodotti Pexa-Vec e nivolumab per il trattamento del tumore del fegato

Not yet recruiting
1/2
55
Europe
pexastimogene devacirepvec, nivolumab, [Pexa-Vec], [nivolumab], Suspension for injection, Concentrate for solution for infusion, OPDIVO - 10 MG/ML- CONCENTRATO PER SOLUZIONE PER INFUSIONE- USO ENDOVENOSO- FLACONCINO (VETRO)- 4 ML- 1 FLACONCINO
TRANSGENE SA, TRANSGENE
Hepatocellular carcinoma Carcinoma epatocellulare, Liver cancer Tumore del fegato, Diseases [C] - Cancer [C04]
 
 
NCT03206073: A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Checkmark Results in combination with Pexa-Vec with failed MSS and MSI-H colorectal cancer
Jan 2019 - Jan 2019: Results in combination with Pexa-Vec with failed MSS and MSI-H colorectal cancer
Completed
1/2
34
US
Durvalumab, MEDI-4736, Tremelimumab, CP-675,206, Pexa-Vec, Pexa-Vec, INN pexastimogene devacirepvec
National Cancer Institute (NCI)
Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma, Refractory Cancer, Colorectal Neoplasms
09/20
06/22
NCT04849260: Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma

Recruiting
1/2
54
RoW
Pexa-Vec combined with ZKAB001, ZKAB001 monotherapy
Lee's Pharmaceutical Limited
Local Progression or Metastatic Melanoma With Failed First-line Treatment
05/22
05/23
METROmaJX, NCT02630368: A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma

Checkmark Results for HER2-ve breast cancer and soft tissue sarcoma in combination with metronomic cyclophosphamide
Sep 2018 - Sep 2018: Results for HER2-ve breast cancer and soft tissue sarcoma in combination with metronomic cyclophosphamide
Recruiting
1/2
197
Europe
Cyclophosphamide and JX-594 dose escalation, Brand name : ENDOXAN, Brand name: Pexa-Vec, Cyclophosphamide and JX-594, Cyclophosphamide, Avelumab and JX-594 and Cyclophosphamide, Brand name: ENDOXAN, Brand name: Avelumab
Institut Bergonié, National Cancer Institute, France, Fondation ARC, Merck Sharp & Dohme LLC, Transgene
Solid Tumors, Soft-tissue Sarcoma, Breast Cancer
05/23
11/24
Immuncell-LC (GCC4002) / GC Biopharma
NCT04969731: Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

Recruiting
3
408
RoW
Immuncell-LC, Autologous activated T lymphocyte, Gemcitabine
GC Cell Corporation
Pancreatic Ductal Adenocarcinoma
12/26
06/27
NCT02856815: Safety and Efficacy of "Immuncell-LC" in TACE Therapy

Completed
2
76
RoW
Immuncell-LC
GC Cell Corporation
Carcinoma, Hepatocellular
08/20
09/22
NCT03983967: Evaluate the Efficacy and Safety of 'Immuncell-LC' in Patients Undergoing Liver Transplantation

Completed
1/2
19
RoW
Immuncell-LC
GC Cell Corporation
Liver Transplantation
09/21
08/22
NCT05053295: Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo) in Subjects With Advanced or Recurrent Gastric Cancer

Recruiting
N/A
20
RoW
autologous activated T lymphocyte, Immuncell-LC (Autologous activated T lymphocyte),
Gangnam Severance Hospital
Relapsed or Advanced Gastric Adenocarcinoma, Gastro-esophageal Junction Cancer
07/23
09/23
NCT06620510: Retrospective Study of Long-Term Survival of "Immuncell-LC" in Patients Undergoing Curative Resection for HCC in Korea

Not yet recruiting
N/A
230
NA
Immuncell-LC, No Interventions
GC Cell Corporation
Hepatocellular Carcinoma
12/24
07/25
HyPoietin (epoetin alfa biosimilar) / GC Biopharma, Genexine, Fosun Pharma
NCT04155125: A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient

Completed
3
391
RoW
efepoetin alfa, Mircera
PT Kalbe Genexine Biologics, Novotech (Australia) Pty Limited
Anaemia Associated With Chronic Kidney Disease
03/22
06/23
NCT06466785: A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

Recruiting
3
429
RoW
Efepoetin Alfa, GX-E4, Darbepoetin Alfa, Aranesp®
Genexine, Inc., PT Kalbe Genexine Biologics
Anemia of Chronic Kidney Disease
12/26
09/27
GX-E4-HV-003, NCT06490939: Clinical Trial of Efepoetin Alfa in Healthy Subjects

Recruiting
1
40
RoW
Efepoetin Alfa, GX-E4
Genexine, Inc.
Healthy
02/25
10/25
Neulapeg (pegfilgrastim biosimilar) / GC Biopharma
NCT02840539: Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma

Completed
2
19
RoW
Bortezomib, Cytarabine, Dexamethasone, Pegteograstim, Protezomib, Cytarabine, Dexamethasone, Neulapeg
Seoul National University Hospital, Consortium for Improving Survival of Lymphoma
Mantle Cell Lymphoma
03/21
12/22
NCT06353581: Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX

Active, not recruiting
2
78
RoW
Neulapeg, Control
Yonsei University
Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
05/24
05/24
Barycela (varicella II vaccine) / GC Biopharma
NCT05422508: Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

Recruiting
2
230
RoW
MG1111 (BARICELA), VARIVAX, Suduvax
Green Cross Corporation
Varicella
06/25
06/27
NCT05664152: An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years

Not yet recruiting
N/A
250
NA
MG1111
GC Biopharma Corp
Varicella Zoster Virus Infection
04/23
06/23
Hunterase (recombinant human iduronate-2-sulfatase) / GC Biopharma
NCT05422482: A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ

Active, not recruiting
1
12
RoW
GC1123
GC Biopharma Corp
Mucopolysaccharidosis II, Hunter Syndrome
06/27
06/27
GC3111A / GC Biopharma
NCT06997627: A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults

Recruiting
1/2
120
RoW
GC3111B, Boostrix®
GC Biopharma Corp
Tetanus-diphtheria-acellular Pertussis (Tdap)
05/26
05/26
Hepabig-gene (lenvervimab) / GC Biopharma
NCT05686759: A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.

Recruiting
3
105
RoW
Undiluted I.V.-Hepabig inj(GC5103), Diluted I.V.-Hepabig inj(GC5103)
GC Biopharma Corp
Hepatitis B
06/26
06/26
NCT03519113: HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102

Active, not recruiting
2/3
186
RoW
GC1102 80,000 IU, GC1102 100,000 IU, I.V HBIG
Green Cross Corporation
Hepatitis B Infection
03/22
09/22
GC-1118A / GC Biopharma
NCT04077255: EGFR-targeted Therapy for Gastric Cancer

Recruiting
2
19
RoW
Anti-EGFR antibody in combination with weekly paclitaxel, GC-1118 in combination with weekly paclitaxel
National Cancer Center, Korea, Korean Cancer Study Group
Adenocarcinoma of the Stomach
12/23
12/23
MG1113A / GC Biopharma
NCT05493631: A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient

Recruiting
1b
15
RoW
MG1113
GC Biopharma Corp
Hemophilia
07/24
12/24
Enblo (enavogliflozin) / Daewoong Pharma, GC Biopharma, M8 Pharma
ENVELOP, NCT06642623: A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients

Recruiting
4
2862
RoW
Enavogliflozin, Dapagliflozin or Empagliflozin
Yonsei University
Diabetes Mellitus, Type 2, Cardiovascular Diseases, Kidney Diseases
09/29
12/30
NCT06399835: Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

Recruiting
4
120
RoW
Enavogliflozin, Envlo Tab., Pioglitazone, Actos Tab.
Seoul National University Bundang Hospital, Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes
06/26
12/26
ENRICH-PEF, NCT06350487: The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction

Not yet recruiting
4
154
RoW
SGLT2 inhibitor, SGLT2 inhibitor: Enavogliflozin (Brand names: Envlo tab)
Samsung Medical Center
Heart Failure, Preserved Ejection Fraction
12/25
06/26
ENAVO-AF, NCT06528262: Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation

Not yet recruiting
4
390
RoW
Enavogliflozin, Placebo
Yonsei University
Atrial Fibrillation
08/26
08/26
ENDEAVOR-HCM, NCT06580717: ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy

Recruiting
4
200
RoW
enavogliflozin 0.3mg, enavogliflozin Placebo
Yonsei University
Nonobstructive Hypertrophic Cardiomyopathy
11/26
11/26
ENVY, NCT06782139: Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity

Recruiting
4
30
RoW
Enavogliflozin, Placebo
Korea University Anam Hospital, Daewoong Pharmaceutical Co. LTD.
Obesity and Type 2 Diabetes
12/25
12/25
ENAVO-TAVR, NCT05672836: ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement

Recruiting
4
1040
RoW
Enavogliflozin, Standard-of-Care, Standard-of-Care medical therapy
Duk-Woo Park, MD, CardioVascular Research Foundation, Korea, Daewoong Pharmaceutical Co. LTD.
Aortic Valve Stenosis, Heart Failure
12/26
04/27
NCT06141980: Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus

Not yet recruiting
3
134
NA
DWP16001 0.3 mg
Daewoong Pharmaceutical Co. LTD.
T2DM (Type 2 Diabetes Mellitus)
09/25
09/25
NCT05505994: The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin

Active, not recruiting
3
340
RoW
DWP16001, DWP16001 tablet, Dapagliflozin, Dapagliflozin tablet, DWP16001 Placebo, DWP16001 Placebo tablet, Dapagliflozin Placebo, Dapagliflozin Placebo tablet
Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
02/24
09/24
ENHANCE-I, NCT05466643: A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus

Recruiting
3
240
RoW
DWP16001 0.3mg, DWP16001 Placebo
Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes Mellitus
09/24
09/24
NCT06606093: Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients

Not yet recruiting
3
348
RoW
DWP16001 Placebo, DWP16001 0.3mg
Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetic Nephropathy
09/26
01/27
EVENT, NCT06027307: Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation

Recruiting
3
540
RoW
Enavogliflozin, Envlo (brand name), Placebo
Asan Medical Center, Daewoong Pharmaceutical Co. LTD.
Tricuspid Regurgitation, Heart Failure With Preserved Ejection Fraction
12/26
10/27
NCT05207176: Study to Evaluate the Safety and PK Properties of DWP16001 in Healthy Subjects With Various Ethnicities

Not yet recruiting
1
24
NA
DWP16001
Daewoong Pharmaceutical Co. LTD.
Healthy
04/22
08/22
NCT05321732: The Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy Adults

Enrolling by invitation
1
24
RoW
DWP16001, DWP202010
Daewoong Pharmaceutical Co. LTD.
Healthy Volunteers
08/22
08/22
NCT05500898: Drug-Drug Interaction of DWP16001 in Combination With DWC202204 and DWC202205 in Healthy Male Adults

Not yet recruiting
1
53
NA
DWP16001, DWC202204+DWC202205, DWP16001+DWC202204+DWC202205
Daewoong Pharmaceutical Co. LTD.
Healthy
10/22
02/23
NCT05737771: To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination

Recruiting
1
40
RoW
DWC202213, DWJ1563, DWP16001
Daewoong Pharmaceutical Co. LTD.
FDC, Diabetes Mellitus, Type 2
03/23
06/23
NCT05797922: To Evaluate the Effect of Food on the Safety and PK Characteristics of DWP16001 in Healthy Adult Volunteers

Recruiting
1
32
RoW
DWP16001, DWP16001 0.3mg
Daewoong Pharmaceutical Co. LTD.
Healthy
05/23
11/23
NCT05747664: To Compare the Safety and PK/PD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic Function

Recruiting
1
24
RoW
DWP16001, DWP16001 0.3mg
Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus, Type 2
04/24
04/24
DW_DWP16001112, NCT06644404: Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults

Not yet recruiting
1
34
RoW
DWP16001 0.3mg, DWC202407 1,000mg, DWC202408 2mg
Daewoong Pharmaceutical Co. LTD.
Healthy
12/24
04/25
NCT06427083: Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus

Recruiting
N/A
240
RoW
Envlo Tablet, Envolomet SR Tablet
Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes Mellitus
12/25
06/26
NCT05926414: To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus

Active, not recruiting
N/A
15000
RoW
Enavogliflozin, Envlo Tablet, Envlomet SR Tablet
Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus, Type 2
01/25
06/25
NCT06647888: Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia

Recruiting
N/A
12000
RoW
Envlo Tablet, Enavogliflozin 0.3mg, Envlomet SR Tablet, Enavogliflozin 0.3mg/ Metformin1,000mg
Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus, Type 2
12/25
06/26
AlloNK (GCC4001) / Artiva Biotherapeutics
NCT06991114: AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Recruiting
2
90
US
Allogeneic NK Cells
Artiva Biotherapeutics, Inc.
Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease
01/28
01/29
LuminICE-203, NCT05883449: Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL

Recruiting
2
154
US
AFM13, AB-101, Cyclophosphamide, Fludarabine, Interleukin-2
Affimed GmbH, Artiva Biotherapeutics, Inc.
Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma
04/26
11/27
NCT04673617: AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Active, not recruiting
1/2
45
US
AB-101, Rituximab, Interleukin-2, Cyclophosphamide, Fludarabine, Bendamustine
Artiva Biotherapeutics, Inc.
Non Hodgkin Lymphoma
08/24
12/25
AB-101-03, NCT06265220: AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Recruiting
1
51
US
AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab
Artiva Biotherapeutics, Inc.
Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLE
08/27
08/27
IRIS-RD-01, NCT06581562: Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

Recruiting
1
30
US
AB-101, ALLONK, RITUXIMAB, CYCLOPHOSPHAMIDE, FLUDARABINE, Rituximab, Cyclophosphamide, Fludarabine
IRIS Research and Development, LLC, Artiva Biotherapeutics, Inc.
Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
07/27
12/28
GCC2003 / Artiva Biotherapeutics
NCT05678205: A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

Not yet recruiting
1/2
133
US, RoW
AB-201, Cyclophosphamide, Fludarabine
Artiva Biotherapeutics, Inc.
Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
04/27
04/27
Laennec (human placenta hydrolyzate) / GC Biopharma
NCT06493799: In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop

Not yet recruiting
3
226
NA
LAENNEC (Human Placenta Hydrolysate) IV, LAENNEC (Human Placenta Hydrolysate) SC
Green Cross Wellbeing
Chronic Liver Disease
12/25
12/25
human tonsil-derived mesenchymal stem cell (CT303) / GC Biopharma
NCT05238532: Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With ARDS

Withdrawn
1
8
RoW
CT303
GC Cell Corporation
Acute Respiratory Distress Syndrome
02/23
02/23
NCT05258331: Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis

Recruiting
1
24
RoW
CT303
GC Cell Corporation
Moderate to Severe Plaque Psoriasis
08/24
12/24
quadrivalent cell-culture based influenza vaccine (GC3106) / GC Biopharma
NCT06020118: Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations

Completed
4
455
US
Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster), Sequential Vaccination (Influenza vaccine then mRNA COVID booster), Sequential Vaccination (mRNA COVID booster then Influenza vaccine)
Duke University, Centers for Disease Control and Prevention, Arizona State University, University Hospitals Cleveland Medical Center, University of Pittsburgh, Washington University School of Medicine, Valleywise Health, Cleveland VA Medical Center, Senders Pediatrics
Influenza, COVID-19
03/24
05/24
Suduvax / GC Biopharma
No trials found
GCFLU Quadrivalent (quadrivalent flu vaccine) / GC Biopharma
No trials found
AFM13/AB-101 / Affimed, GC Biopharma
No trials found
GCC2005 / Artiva Biotherapeutics
No trials found

Download Options